TD Waterhouse Canada Inc. cut its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 41.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,923 shares of the medical research company’s stock after selling 5,717 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $2,065,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in IQVIA in the 2nd quarter worth about $2,811,292,000. Canada Pension Plan Investment Board bought a new stake in IQVIA in the 2nd quarter valued at about $240,911,000. Bank of America Corp DE purchased a new stake in IQVIA during the second quarter valued at about $235,551,000. Legal & General Group Plc purchased a new stake in IQVIA during the second quarter valued at about $211,342,000. Finally, Bank of New York Mellon Corp purchased a new stake in IQVIA during the second quarter valued at about $180,296,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
IQVIA Stock Performance
Shares of IQV opened at $276.56 on Thursday. The stock’s 50-day simple moving average is $262.40 and its 200 day simple moving average is $215.24. The stock has a market capitalization of $45.52 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 2.35 and a beta of 1.17. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $277.40.
IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.55 EPS for the current fiscal year.
Insider Transactions at IQVIA
In related news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 15,581 shares of company stock valued at $3,796,021. Company insiders own 1.70% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on IQV shares. UBS Group assumed coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 target price for the company. HSBC reissued a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Truist Financial reaffirmed a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. Finally, Robert W. Baird lifted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $276.00.
Read Our Latest Stock Report on IQVIA
IQVIA Profile
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
Read More
- Five stocks we like better than IQVIA
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
